* cdc48-aid rub1∆ cdc48-aid * Cullin neddylation is not essential for CMG helicase ubiquitylation in budding yeast. (A) Control (YSS47) and rub1∆ (YPM35) cells were grown at 24˚C, synchronised in G1 phase by addition of mating pheromone, and then released into S phase. Samples were taken at the indicated times and processed for flow-cytometry. The samples marked with asterisks were used to make cell extracts. (B) Samples from the same experiments were used to monitor CMG helicase ubiquitylation in yeast cell extracts, as in Figure 1A . (C) cdc48-aid control cells (YMM228) and cdc48-aid rub1∆ cells (YPM29) were grown at 24˚C, synchronised in G1 phase by addition of mating pheromone, and then released into medium containing 0.2 M hydroxyurea (HU) at 24˚C, until more than 80% of the cells had budded. The auxin indoleacetic acid was then added to 500 µM, in order to deplete Cdc48-aid. The cultures were subsequently released into fresh medium containing auxin but lacking HU, so that cells were able to complete S phase. Samples were taken at the indicated times and processed for flow-cytometry. The samples marked with asterisks were also used to prepare 'high-salt' cell extracts (containing 700mM potassium acetate), in order to monitor in vivo CMG ubiquitylation in the absence of in vitro ubiquitylation. (D) TAP-Sld5 was isolated by immunoprecipitation from extracts of the indicated samples from (C). Purified proteins employed in this study. The indicated factors were expressed in recombinant form and purified as described in Methods, before resolution in a 4-12% Bis-Tris gel, and staining with colloidal Coomassie blue. (YPM164), were grown at 30˚C in raffinose-containing media until mid-exponential phase. The ProteinA-tagged versions of Dia2 were then induced by addition of galactose for 2 hours. Samples was taken at the indicated times and processed for flow-cytometry. The samples marked with asterisks were also used to prepare cell extracts. (B) ProteinA-tagged Dia2 was then isolated and processed as in Figure 3B , either using 50 µM wild type ubiquitin (wt Ubi) or 50 µM lysine-free ubiquitin (K0 Ubi), before immunoblotting of the indicated factors. 
